- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
March 25, 2024Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Third Quarter
This New ANDA Cases chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Actelion Pharms. US, Inc. v. MSN Labs. Private Ltd., 23-0731 (D. Del.) | 6-Jul-23 | Hon. Gregory B. Williams | Uptravi® (selexipag for injection) | 8,791,122 9,284,280 |
| Biogen Inc. v. Zydus Worldwide DMCC, 23-0732 (D. Del.) | 6-Jul-23 | Hon. Gregory B. Williams | Vumerity® (diroximel fumarate delayed-release capsules) | 8,669,281 9,090,558 10,080,733 |
| Actelion Pharms. Ltd. v. Apotex Inc., 23-0734 (D. Del.) | 6-Jul-23 | Hon. Colm F. Connolly | Opsumit® (macitentan tablets) | 7,094,781 |
| CMP Development, LLC v. Hetero USA, Inc., 23-0747 (D. Del.) | 10-Jul-23 | Hon. Maryellen Noreika | CaroSpir® (spironolactone oral suspension) | 9,757,394 10,493,083 10,624,906 10,660,907 10,888,570 11,389,461 11,395,828 11,491,166 |
| AbbVie Inc. v. Lupin Ltd., 23-0750 (D. Del.) | 10-Jul-23 | Hon. Richard G. Andrews | Orilissa® (elagolix sodium tablets) | 11,542,239 |
| Mitsubishi Tanabe Pharma Corp. v. Cipla USA Inc., 23-0759 (D. Del.) | 12-Jul-23 | Hon. Colm F. Connolly | Radicava Ors® (edaravone oral suspension) | 10,987,341 11,241,416 11,478,450 |
| Gilead Sciences, Inc. v. Apotex Inc., 23-0774 (D. Del.) | 14-Jul-23 | Hon. Maryellen Noreika | Genvoya® (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide tablets) | 10,039,718 |
| Gilead Sciences, Inc. v. Apotex Inc., 23-0775 (D. Del.) | 14-Jul-23 | Hon. Maryellen Noreika | Genvoya® (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide tablets) | 8,754,065 9,296,769 |
| Alkermes Pharma Ireland Ltd. v. Slayback Pharma LLC, 23-3794 (D.N.J.) | 14-Jul-23 | Hon. Georgette Castner | Anjeso® (meloxicam injection) | 10,463,673 10,471,067 10,709,713 10,881,663 11,458,145 |
| Azurity Pharms., Inc. v. Cosette Pharms., Inc., 23-3830 (D.N.J.) | 18-Jul-23 | Hon. Evelyn Padin | Firvanq® (vancomycin HCl oral solution) | 11,638,692 |
| Oyster Point Pharma, Inc. v. Apotex, Inc., 23-3860 (D.N.J.) | 19-Jul-23 | Hon. Julien Xavier Neals | Tyrvaya® (varenicline solution) | 9,504,644 9,504,645 9,532,944 9,597,284 10,456,396 11,224,598 |
| Allergan Holdings Unlimited Co. v. MSN Labs. Private Ltd., 23-0794 (D. Del.) | 21-Jul-23 | Hon. Richard G. Andrews | Viberzi® (eluxadoline tablets) | 11,484,527 |
| Allergan Holdings Unlimited Co. v. Sun Pharm. Indus. Ltd., 23-0795 (D. Del.) | 21-Jul-23 | Hon. Richard G. Andrews | Viberzi® (eluxadoline tablets) | 11,484,527 |
| Boehringer Ingelheim Pharms., Inc. v. Alvogen, Inc., 23-3911 (D.N.J.) | 21-Jul-23 | Hon. Kevin McNulty | Spiriva® HandiHaler® (tiotropium bromide inhalation powder) | 9,010,323 |
| GW Research Ltd. v. Teva Pharms., Inc., 23-3914 (D.N.J.) | 21-Jul-23 | Hon. Michael Farbiarz | Epidiolex® (cannabidiol oral solution) | 11,633,369 |
| Currax Pharms. LLC v. Ajanta Pharma Ltd., 23-3937 (D.N.J.) | 24-Jul-23 | Hon. Christine P. O’Hearn | Silenor® (doxepin HCl tablets) | 7,915,307 8,513,299 9,107,898 9,486,43 9,572,814 9,861,607 10,238,620 10,653,660 10,653,662 11,110,074 |
| Janssen Pharmaceutica NV v. Natco Pharma Ltd., 23-3959 (D.N.J.) | 25-Jul-23 | Hon. Brian R. Martinotti | Balversa® (erdafitinib tablets) | 9,902,714 11,077,106 |
| Supernus Pharms., Inc. v. Ascent Pharms. Inc., 23-4015 (D.N.J.) | 26-Jul-23 | Hon. Georgette Castner | Trokendi XR® (topiramate extended-release capsules) | 8,298,576 8,298,580 8,663,683 8,877,248 8,889,191 8,992,989 9,549,940 9,555,004 9,622,983 10,314,790 |
| Novo Nordisk Inc. v. Lupin Ltd., 23-4027 (D.N.J.) | 27-Jul-23 | Hon. Georgette Castner | Victoza® (liraglutide recombinant solution injection) | 8,114,833 9,265,893 |
| Novo Nordisk Inc. v. Lupin Ltd., 23-4031 (D.N.J.) | 27-Jul-23 | Hon. Susan D. Wigenton | Saxenda® (liraglutide recombinant solution injection) | 8,114,833 8,684,969 8,920,383 9,108,002 9,132,239 9,457,154 9,616,180 9,687,611 9,775,953 9,861,757 10,220,155 10,357,616 10,376,652 11,097,063 11,311,679 RE46,363 |
| Astellas Pharma Inc. v. Lupin Ltd., 23-0819 (D. Del.) | 28-Jul-23 | Hon. Gregory B. Williams | Myrbetriq® (mirabegron extended-release tablets) | 11,707,451 |
| Supernus Pharms., Inc. v. Ascent Pharms. Inc., 23-5720 (E.D.N.Y.) | 28-Jul-23 | Hon. Gary R. Brown | Trokendi XR® (topiramate extended-release capsules) | 8,298,576 8,298,580 8,663,683 8,877,248 8,889,191 8,992,989 9,549,940 9,555,004 9,622,983 10,314,790 |
| Genentech, Inc. v. Sandoz, Inc., 23-4085 (D.N.J.) | 31-Jul-23 | Hon. Julien Xavier Neals | Esbriet® (pirfenidone tablets) | 10,188,637 |
| Azurity Pharms., Inc. v. Zydus Worldwide DMCC, 23-0833 (D. Del.) | Aug. 2, 2023 | Hon. Maryellen Noreika | Edarbi® (azilsartan medoxomil tablets) Edarbyclor® (azilsartan medoxomil / chlorthalidone tablets) | 9,066,936 9,169,238 9,387,249 |
| Azurity Pharms., Inc. v. Zydus Worldwide DMCC, 23-4152 (D.N.J.) | Aug. 3, 2023 | Hon. Robert Kirsch | Edarbi® (azilsartan medoxomil tablets) Edarbyclor® (azilsartan medoxomil / chlorthalidone tablets) | 9,066,936 9,169,238 9,387,249 |
| Boehringer Ingelheim Pharms. Inc. v. Ajanta Pharma Ltd., 23-0847 (D. Del.) | Aug. 4, 2023 | Hon. Colm F. Connolly | Glyxambi® (empagliflozin / linagliptin tablets) | 8,551,957 9,949,998 10,258,637 11,090,323 |
| Boehringer Ingelheim Pharms. Inc. v. Ajanta Pharma Ltd., 23-0848 (D. Del.) | Aug. 4, 2023 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 9,949,998 10,258,637 11,090,323 |
| Boehringer Ingelheim Pharms. Inc. v. Ajanta Pharma Ltd., 23-0849 (D. Del.) | Aug. 4, 2023 | Hon. Colm F. Connolly | Synjardy® (empagliflozin / metformin HCl tablets) | 10,258,637 11,090,323 |
| Par Pharm., Inc. v. Zydus Pharms. (USA) Inc., 23-0866 (D. Del.) | Aug. 8, 2023 | Hon. Richard G. Andrews | Chantix® (varenicline tartrate tablets) | 11,717,524 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. v. Aurobindo Pharma Ltd., 23-0877 (D. Del.) | Aug. 10, 2023 | Hon. Maryellen Noreika | Velphoro® (sucroferric oxyhydroxide tablets) | 9,561,251 10,624,855 10,682,376 10,695,367 10,925,896 10,925,897 10,933,090 11,013,761 11,013,762 11,234,938 11,446,252 |
| Pfizer Inc. v. Dexcel Pharma Technologies Ltd., 23-0879 (D. Del.) | Aug. 10, 2023 | Hon. Gregory B. Williams | Vyndamax® (tafamidis capsules) | 7,214,695 7,214,696 9,770,441 |
| AbbVie Inc. v. Alkem Labs. Ltd., 23-0881 (D. Del.) | Aug. 10, 2023 | Hon. Richard G. Andrews | Orilissa® (elagolix sodium tablets) | 11,542,239 |
| AbbVie Inc. v. Zenara Pharma Private Ltd., 23-0892 (D. Del.) | Aug. 11, 2023 | Hon. Richard G. Andrews | Orilissa® (elagolix sodium tablets) | 11,542,239 |
| Fresenius Kabi USA, LLC v. Amneal Pharms. LLC, 23-4343 (D.N.J.) | Aug. 11, 2023 | Hon. Claire C. Cecchi | Diprivan® (propofol injection) | 8,476,010 |
| Allergan, Inc. v. Amneal Pharms. of New York, LLC, 23-6208 (E.D.N.Y.) | Aug. 17, 2023 | Hon. Gary R. Brown | Lumigan® (bimatoprost ophthalmic solution) | 7,851,504 8,278,353 8,299,118 8,309,605 8,338,479 8,524,777 8,586,630 8,772,338 8,933,120 8,933,127 9,155,716 9,241,918 |
| Pfizer Inc. v. Cipla Ltd., 23-0909 (D. Del.) | Aug. 18, 2023 | Hon. Gregory B. Williams | Vyndamax® (tafamidis capsules) | 9,770,441 |
| Theravance Biopharma R&D IP, LLC v. Eugia Pharma Specialties Ltd., 23-6667 (D.N.J.) | Aug. 21, 2023 | Hon. Karen M. Williams | Yupelri® (revefenacin inhalation solution) | 11,691,948 |
| Pfizer Inc. v. Aurobindo Pharma Ltd., 23-0923 (D. Del.) | Aug. 23, 2023 | Hon. Gregory B. Williams | Vyndaqel® (tafamidis meglumine capsules) | 7,214,695 |
| Pfizer Inc. v. Zenara Pharma Private Ltd., 23-0924 (D. Del.) | Aug. 23, 2023 | Hon. Gregory B. Williams | Vyndamax® (tafamidis capsules) | 9,770,441 |
| Alkermes Pharma Ireland Ltd. v. Nanjing Delova Biotech Co., Ltd., 23-9763 (D.N.J.) | Aug. 24, 2023 | Hon. Georgette Castner | Anjeso® (meloxicam injection) | 9,974,746 10,709,713 10,881,663 11,458,145 |
| Endo Par Innovation Co., LLC v. BPI Labs, LLC, 23-1953 (M.D. Fl.) | Aug. 29, 2023 | Hon. William F. Jung | Adrenalin® (epinephrine injection) | 9,119,876 9,295,657 |
| Curia IP Holdings, LLC v. Salix Pharms., Ltd., 23-13764 (D.N.J.) | Aug. 31, 2023 | Hon. Karen M. Williams | Xifaxan® (rifaximin tablets) | 11,739,099 |
| Amicus Therapeutics US, LLC v. Lupin Ltd., 23-0964 (D. Del.) | Sept. 1, 2023 | Hon. Christopher J. Burke | Galafold® (migalastat capsules) | 9,000,011 9,987,263 10,383,864 10,406,143 10,925,866 10,813,921 RE48,608 |
| Par Pharm., Inc. v. Mankind Pharma Ltd., 23-0399 (E.D. Tex.) | Sept. 1, 2023 | Hon. Rodney Gilstrap | Varenicline Tartrate | 11,717,524 |
| Par Pharm., Inc. v. Alkem Labs. Ltd., 23-0400 (E.D. Tex.) | Sept. 1, 2023 | Hon. Rodney Gilstrap | Varenicline Tartrate | 11,717,524 |
| United Therapeutics Corp. v. Liquidia Technologies, Inc., 23-0975 (D. Del.) | Sept. 5, 2023 | Hon. Richard G. Andrews | Tyvaso® (treprostinil inhalation solution) Tyvaso DPI® (treprostinil inhalation powder) Yutrepia® (treprostinil inhalation powder) | 10,716,793 |
| Azurity Pharms., Inc. v. Annora Pharma Private Ltd., 23-18420 (D.N.J.) | Sept. 7, 2023 | Hon. Christine P. O’Hearn | Qbrelis® (lisinopril oral solution) | 9,463,183 9,616,096 9,814,751 10,039,800 10,265,370 10,406,199 10,940,177 11,179,434 |
| Celgene Corp. v. Teva Pharms., Inc., 23-1008 (D. Del.) | Sept. 13, 2023 | Hon. Richard G. Andrews | Onureg® (azacitidine tablets) | 8,846,628 11,571,436 |
| Axsome Malta Ltd. v. Alkem Labs Ltd., 23-20354 (D.N.J.) | Sept. 13, 2023 | Hon. Madeline Cox Arleo | Sunosi® (solriamfetol tablets) | 8,440,715 8,877,806 9,604,917 10,351,517 10,195,151 10,512,609 11,439,597 10,912,754 10,959,976 11,160,779 10,940,133 11,560,354 11,648,232 |
| Heron Therapeutics, Inc. v. Mylan Pharms. Inc., 23-1015 (D. Del.) | Sept. 15, 2023 | Hon. William C. Bryson | Civanti® (aprepitant injection) | 9,561,229 9,808,465 9,974,742 9,974,793 9,974,794 10,500,208 10,624,850 10,953,018 11,173,118 |
| Celgene Corp. v. Natco Pharma Ltd., 23-1019 (D. Del.) | Sept. 18, 2023 | Hon. Richard G. Andrews | Onureg® (azacitidine tablets) | 8,846,628 11,571,436 |
| Fresenius Kabi USA, LLC v. Meitheal Pharms., Inc., 23-1050 (D. Del.) | Sept. 26, 2023 | Hon. Colm F. Connolly | Diprivan® (propofol injectable emulsion) | 8,476,010 |
| Orphalan SA v. Novitium Pharma LLC, 23-1079 (D. Del.) | Sept. 29, 2023 | Hon. Gregory B. Williams | Cuvrior® (triethylenetetramine tetrachloride tablets) | 10,988,436 11,072,577 |
| Azurity Pharms., Inc. v. Teva Pharms., Inc., 23-1080 (D. Del.) | Sept. 29, 2023 | Hon. Maryellen Noreika | Edarbyclor® (azilsartan medoxomil / chlorthalidone tablets) | 9,066,936 9,169,238 9,387,249 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.